Samsung Enters Contract Biopharma Sector

Electronics giant Samsung says it has formed a joint venture company with Quintiles, a top-tier pharma services group to support its entry into the contract manufacture of biopharmaceuticals. Samsung aplans to commercialize generic biopharmaceuticals - dubbed biosimilars - by 2016, and expand into innovative biologics thereafter.   Under an agreement signed during the past week, Quintiles takes a minority 10% stake in teh jv and will investment of approximately $30 million in the business. Samsung will own the other 90% of the jv company...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers